Cargando…

Current insight into the regulation of PD-L1 in cancer

The molecular mechanisms underlying cancer immune escape are a core topic in cancer immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by exploiting the inhibitory programmed cell-death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1, CD274) immune checkpoint....

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhuandi, Yu, Xibao, Xu, Ling, Li, Yangqiu, Zeng, Chengwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338491/ https://www.ncbi.nlm.nih.gov/pubmed/35907881 http://dx.doi.org/10.1186/s40164-022-00297-8

Ejemplares similares

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

NRF2 activation induced by PML‐RARα promotes microRNA 125b‐1 expression and confers resistance to chemotherapy in acute promyelocytic leukemia
por: Yu, Xibao, et al.
Publicado: (2021)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells
por: Zeng, Chengwu, et al.
Publicado: (2014)

Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia
por: Zeng, Chengwu, et al.
Publicado: (2015)

Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia
por: Li, Kehan, et al.
Publicado: (2021)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells
por: Zeng, Chengwu, et al.
Publicado: (2018)

Roles of METTL3 in cancer: mechanisms and therapeutic targeting
por: Zeng, Chengwu, et al.
Publicado: (2020)

Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis
por: Nie, Dingrui, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-L1: expression regulation
por: Zhou, Yu-Jie, et al.
Publicado: (2023)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance
por: Veluswamy, Priya, et al.
Publicado: (2020)

High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia
por: Yu, Xibao, et al.
Publicado: (2023)

The importance of genomic predictors for clinical outcome of hematological malignancies
por: Chen, Cunte, et al.
Publicado: (2021)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity
por: Yadollahi, Pedram, et al.
Publicado: (2021)

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
por: Yi, Ming, et al.
Publicado: (2022)

Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
por: Ran, Xiongwen, et al.
Publicado: (2017)

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
por: Li, Jia-Xin, et al.
Publicado: (2019)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Regulation of PD-L1 expression in the tumor microenvironment
por: Yi, Ming, et al.
Publicado: (2021)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
por: Ma, Weijie, et al.
Publicado: (2016)

Alteration of gene expression profile in CD3(+) T-cells after downregulating MALT1
por: Wang, Xu, et al.
Publicado: (2018)

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

PD-1/PD-L Axis in Neuroinflammation: New Insights
por: Manenti, Susanna, et al.
Publicado: (2022)

The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer
por: Glorieux, Christophe, et al.
Publicado: (2021)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
por: Liu, Chang, et al.
Publicado: (2021)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 and DNA Damage Response in Cancer
por: Kciuk, Mateusz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7rjuibsurbtc4lb9qvjjaetj4n